Before Man And Quisinostat Crash

The primary endpoint is 1-year OS and there are multiple levels of quality control to ensure validity (clinicaltrials.gov). How Best Can Response to FFX Therapy be Assessed? Both serologic and radiographic ankyrin response to therapy has come under increasing scrutiny. CA 19-9 has been used for decades as a serum marker in pancreatic cancer in Lewis antigen-positive individuals 52,53. However, this is complicated by the fact that biliary obstruction, pancreatitis, intestinal inflammation, and even elevated blood glucose 54 all lead to an increase in CA 19-9. While there is evidence that there is a difference in outcome between no responders and stable or good responders 55,56, there are opposing findings suggesting that there may be no correlation 57, and additional data are awaited. Change in tumor dimensions, as assessed on CT scan and/or MRI, is both challenging to measure and often insignificant 58. In a study of 129 patients with borderline resectable tumors, post therapy, presurgical imaging suggested that only 1% had been down staged, 78% had no change, and 21% had progressive disease 59. In fact, 66% were able to undergo resection with 95% R0 resections. Provided the patient has acceptable performance status and no evidence of metastatic disease, even where there is no obvious radiographic response, surgery should proceed as pathology may indicate clear-cut treatment effect 60. Whether pathologic response has any meaning in the clinical context awaits further clarification, but initial reports suggest that more than 5% viable cells in the final specimen portends a bad outcome 61,62. While endoscopic ultrasound GSK-3 assay can be valuable 63, novel ways of imaging the tumor, such as perfusion imaging 64, dynamic PET scans 65 and routine CT scan derived mass transport parameters, are increasingly being incorporated into investigational algorithms 66. How is FFX Optimally Combined with Radiation Therapy? Many protocols in borderline and locally advanced, unresectable disease switch to radiation therapy following initial FFX 51. However, the precise role of radiation in these settings is the subject of ongoing debate. The LAP 07 study found that in locally advanced disease, chemo/radiation had no effect on OS compared to continued chemotherapy alone (over 40% of patients developed metastatic disease prior to being randomized to radiation or not) in those patients stable Quisinostat nmr after an initial phase of gemcitabine �� erlotinib 67. Updated results in 2014 suggested less local recurrence in the CRT arm (34% vs. 65%, P?